Our Leadership
Sam Altman
Sam Altman is the CEO of OpenAI and a current advisor and former president of Y Combinator. He studied computer science at Stanford, and while there, worked in the AI lab.
Mark Fishman, MD
Dr. Mark Fishman is currently a professor at the Harvard Department of Stem Cell and Regenerative Biology, Chief of the Pathways Consult Service at Massachusetts General Hospital, and was the founding President of the Novartis Institutes for Biomedical Research (NIBR).
Ken Somberg, MD
Dr. Ken Somberg is the Chief Medical Officer of TrialSpark, where he oversees the build-out of TrialSpark’s drug development offerings and end-to-end trial services in addition to contributing to company strategy and operations.
Benjamine Liu
Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development and the clinical trial process. Before TrialSpark, Ben trained as a computational biologist at Oxford as a Rhodes Scholar.
